Accelerated Approval: US FDA, Covis Navigate Novel Issues With Makena’s Withdrawal

Ahead of the final withdrawal decision, FDA terminated internal separation of functions so that the Office of the Commissioner and CDER could coordinate next steps; Makena’s NDA approval has been withdrawn, but the product’s website lives on, albeit with a pop-up window explaining the regulatory action.

Makena popup
A pop-up about FDA's withdrawal order greets visitors to the Makena.com product website. • Source: Makena

The US Food and Drug Administration and Covis Pharma are navigating uncharted waters with the agency-ordered withdrawal of preterm birth prevention drug Makena (hydroxyprogesterone caproate) for lack of demonstrated efficacy.

Makena’s label carried only one indication – to reduce the risk of preterm birth in women with a singleton pregnancy...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Post-Marketing Regulation & Studies

More from Product Reviews

  • data

    New EU Filings

     
    • By 

    <p>Executive Summary</p> <p>Zanidatamab, Jazz and BeiGene’s investigational treatment for biliary tract cancer, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.</p>

  • data

    EU CHMP Opinions And MAA Updates

     
    • By 

    <p>Executive Summary</p> This is an update of recommendations from the European Medicines Agency's Committee for Medicinal Products for Human Use on the authorization of new medicines in the EU, and updates on EU marketing authorization changes recommended by the CHMP.

  • EU Biosimilar Filings, Opinions And Approvals

     
    • By 

    <p>Executive Summary</p> <p>A list of EU biosimilar filings, CHMP opinions and EU marketing authorizations, including details of the biosimilar company, the brand name/INN, indication(s), the reference product/company, and the date and type of event.</p>